Year	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	
opulation (millions)	343.85	346.1	348.35	350.6	352.85	355.1	356.94	358.78	360.62	362.46	
6 Prevalance Rate(Episodic Migraine)	12	12	12	12	12	12	12	12	12	12	
6 Episodic Migraine receiving Acute Treatment	82	82	82	82	82	82	82	82	82	82	
Treatment Penetration Rate	88.2013	88.8211	89.379	89.8811	90.333	90.7397	91.1057	91.4352	91.7317	91.9985	
Estimated Use of Relief	37	37	37	37	37	37	37	37	37	37	
6 Market Uptake of Relief	7.5867	17.4949	29.5333	42.3728	57.579	76.1663	92.5678	100	100	100	
Total Patients consuming RELIEF (millions)	0.8377100941	1.958060171	3.34780463	4.861432682	6.681861907	8.935270259	10.95967141	11.94368847	12.0438704	12.14053024	
ear	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	Total pills sold per year (millions) and Revenue generated
otal Patients consuming RELIEF (millions)	0.84	1.96	3.35	4.86	6.68	8.94	10.96	11.94	12.04	12.14	(million \$)
											10000 Total pills sold per year
											(millions)
Total pills sold per year (millions)	75.39	176.23	301.30	437.53	601.37	804.17	986.37	1074.93	1083.95	1092.65	Revenue generated
											7500 (million \$)
Cost of each pill = \$8.5											
Revenue generated (million \$)	640.85	1497.92	2561.07	3719.00	5111.62	6835.48	8384.15	9136.92	9213.56	9287.51	
											5000
											2500
ear	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	
otal pills sold per year (millions)	75.39390847	176.2254154	301.3024167	437.5289414	601.3675716	804.1743234	986.3704268	1074.931963	1083.948336	1092.647722	
Revenue generated (million \$)	640.848222	1497.916031	2561.070542	3718.996002	5111.624359	6835.481748	8384.148628	9136.921683	9213.560857	9287.505633	2025 2026 2027 2028 2029 2030 2031 2032 2033 2034
											2020 2021 2020 2020 2001 2002 2004
											Year